M. B, N. I., Eifell R, Cusso M, Barakat T, Babikir S, Taran D, M. C., Ojimba T, Naqvi S
{"title":"Ekos Thrombolysis for The Management of Ilio-Femoral Dvt at Cumberland Infirmary","authors":"M. B, N. I., Eifell R, Cusso M, Barakat T, Babikir S, Taran D, M. C., Ojimba T, Naqvi S","doi":"10.47829/cos.2022.8503","DOIUrl":null,"url":null,"abstract":"Introduction: Venous-thromboembolism is common vascular disease affecting lower limbs composed of DVT (2/3 of VTE) and PE (1/3 of VTE). The goal of management of DVT is to prevent PE, recurrence or PTS .Anticoagulation was the cornerstone of DVT management to prevent PE or recurrent DVT. Aim: To review our experience and assess efficacy of EKOS® thrombolysis in management of ilio-femoral DVT at Cumberland infirmary focusing on clinical outcome and any post procedure complications. Results: 22 patients had thrombolysis for illiofemoral DVT over 7years in Cumberland infirmary (Females 16 Males 5). Median age 20-89 years. Total number of treatment Sessions; 1 session: 18.18% (n=4), 2 Session: 54.54% (n=12), 3 sessions: 22.73% (n=5), 4 sessions: 04.55% (n=1). Success rate more than 80%: 90.91.7 % (n=20). Further procedures needed, Stents placement %77.27 (n=17), angioplasty 36.36% (n=8). Outcome; Improvement of symptoms in 90.91% % (n=20) leg ulcer healed in 9.52% (n=2). Post procedure complications: Leg swelling 28.6% (n=6) all are short terms resolved within six weeks and just one long standing leg swelling. Post procedure leg pain is in 19.04% (n=4). Ongoing issues were in 9.52% (n=2) and were persistent leg ulcer and PTS in each. One patient had recurrence. No patient had PE/ intracranial bleeding. Conclusion: EKOS is effective in treating acute ilio-femoral DVT with patency at 80% and more at the cessation of treatment, as well as prevention of DVT related long term complication (recurrence-PE and PTS) in comparison of conventional CDT or anticoagulation alone.","PeriodicalId":92767,"journal":{"name":"Clinics of surgery","volume":"61 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinics of surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47829/cos.2022.8503","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Venous-thromboembolism is common vascular disease affecting lower limbs composed of DVT (2/3 of VTE) and PE (1/3 of VTE). The goal of management of DVT is to prevent PE, recurrence or PTS .Anticoagulation was the cornerstone of DVT management to prevent PE or recurrent DVT. Aim: To review our experience and assess efficacy of EKOS® thrombolysis in management of ilio-femoral DVT at Cumberland infirmary focusing on clinical outcome and any post procedure complications. Results: 22 patients had thrombolysis for illiofemoral DVT over 7years in Cumberland infirmary (Females 16 Males 5). Median age 20-89 years. Total number of treatment Sessions; 1 session: 18.18% (n=4), 2 Session: 54.54% (n=12), 3 sessions: 22.73% (n=5), 4 sessions: 04.55% (n=1). Success rate more than 80%: 90.91.7 % (n=20). Further procedures needed, Stents placement %77.27 (n=17), angioplasty 36.36% (n=8). Outcome; Improvement of symptoms in 90.91% % (n=20) leg ulcer healed in 9.52% (n=2). Post procedure complications: Leg swelling 28.6% (n=6) all are short terms resolved within six weeks and just one long standing leg swelling. Post procedure leg pain is in 19.04% (n=4). Ongoing issues were in 9.52% (n=2) and were persistent leg ulcer and PTS in each. One patient had recurrence. No patient had PE/ intracranial bleeding. Conclusion: EKOS is effective in treating acute ilio-femoral DVT with patency at 80% and more at the cessation of treatment, as well as prevention of DVT related long term complication (recurrence-PE and PTS) in comparison of conventional CDT or anticoagulation alone.